GILEAD Aktie

 

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day....

GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity....

FOSTER CITY (dpa-AFX) - Gilead Sciences Inc. (GILD) said Thursday that the U.S. Food and Drug Administration has approved Trodelvy for the first-line treatment of adults with unresectable locally ......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach....

FOSTER CITY (dpa-AFX) - Tuesday, Gilead Sciences, Inc. (GILD) announced that the European Commission has granted marketing authorization for Trodelvy, also known as sacituzumab govitecan-hziy, as ......

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects....

Importance Rank:  1 read more...

Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio....

Dickinson, Andrew D. - Vorstand - Tag der Transaktion: 2026-06-15...

Mercier, Johanna - Vorstand - Tag der Transaktion: 2026-06-15...

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option....

Gilead Sciences (GILD) reached $124.3 at the closing of the latest trading day, reflecting a -1.03% change compared to its last close....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

MOUNT GILEAD, N.C., June 15, 2026 /PRNewswire/ -- McRae Industries, Inc. (Pink Sheets: MCRAA and MCRAB) reported consolidated net revenues for the third quarter of fiscal 2026 of $27,418,000 as compared to $30,870,000 for the third quarter of fiscal 2025. Net earnings for the third......

- Three-year, ~$3M commitment to expand leadership development, strengthen HIV education and engagement, and preserve the HIV movement's history for future generations -SAN FRANCISCO & FOSTER CITY, Calif.--(BUSINESS WIRE)--The National AIDS Memorial together with the Gilead Foundation today announced a transformative three-year, ~$3 million commitment to help preserve the history of the HIV epidemic, expand public education and engagement, and inspire the next generation of leaders advancing access to care. The fight against HIV/AIDS has always depended on more than medicine. It has required scientific innovation, public education, activism, compassion, communities caring for one another through crisis and change, and a shared commitment to ensuring these stories are never lost. The initiative will help expand leadership development for emerging advocates, increase access to the stories preserved within the AIDS Memorial Quilt, elevate community voices through public engagement programs, and support stew...

Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances....

Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Gilead Sciences Inc. and Merck & Co. said an experimental long acting pill combining two HIV medicines had met its primary efficacy goal in final-stage trials....